NEW
Font size
WorksheetsJalra M Quiz
Total questions: 25
Worksheet time: 13mins
Jalra M is preferred for which type of diabetic patients?
Drug naïve Type 2 Diabetes Mellitus
Type 1 Diabetes Mellitus
Gestational Diabetes
Pediatric Diabetes
The tagline for Jalra M’s positioning focuses on:
Fast action and weight loss
Maximizing β-cell preservation
Reducing lipid levels
Improving liver function
The key differentiating factor of Jalra M over competitors is its:
Color coating
Purity seal and precise assay
Flavor
Tablet size
Jalra M shows an impurity level of only:
1.9%
1.5%
1.4%
0.3%
The percentage assay content of Jalra M is:
95%
97.1%
98.3%
100.3%
What does “precise assay” in Jalra M ensure?
Stable HbA1c levels
Weight reduction
Better gastric tolerance
Early insulin secretion
Jalra M’s better dissolution ensures:
Early onset of side effects
Better bioavailability
Increased blood pressure
Reduced compliance
In impurity comparison, which brand had the lowest impurity?
Brand A
Brand B
Brand C
Jalra M
Jalra M’s dissolution percentage compared to others was:
99%
95%
96%
104%
Among competitor brands, which parameter was highest for Jalra M?
Impurity
Dissolution rate
Side effect profile
Tablet hardness
Jalra M’s assay content (100.3%) compared to Brand A (97.9%) indicates:
Better purity and potency
Higher toxicity
Reduced absorption
Need for higher dose
The high dissolution rate in Jalra M leads to:
Rapid disintegration and consistent bioavailability
Extended gastric retention
Reduced glucose absorption
Altered hepatic metabolism
The primary mechanism of Jalra M is to:
Stimulate β-cell regeneration and improve insulin sensitivity
Increase glucagon secretion
Delay gastric emptying only
Inhibit glucose reabsorption in the kidney
The β-cell preservation property of Jalra M helps in:
Sustained glycemic control
Reducing metformin side effects
Enhancing lipid metabolism
Increasing insulin resistance
Jalra M ensures better glycemic control due to its:
High impurity content
Purer formulation and consistent assay
Delayed onset
Dual mechanism on liver
Jalra M belongs to which fixed-dose combination therapy?
DPP-4 inhibitor + Biguanide
SGLT2 inhibitor + Biguanide
GLP-1 agonist + Thiazolidinedione
DPP-4 inhibitor + Sulfonylurea
The “VERI Early” message for Jalra M refers to:
Starting Vildagliptin + Metformin early in T2DM
Verifying HbA1c levels after 6 months
Using it in pre-diabetes stage
Verifying insulin dose titration
Jalra M’s purity claim is supported by:
Random surveys
Data on file and published studies
Animal models
Competitor analysis only
The brand comparison data emphasizes Jalra M’s superiority in:
Dissolution, assay, and impurity profile
Cost, size, and packaging
Branding and advertising
Market share only
Jalra M ensures better glycemic control by:
Stabilizing HbA1c through precise formulation
Acting as a rapid insulin analogue
Replacing sulfonylureas completely
Enhancing glucagon levels
Jalra M’s consistent assay content ensures:
Reduced hypoglycemia risk
Stable therapeutic effect
Fluctuating glucose control
Reduced compliance
The combination of Vildagliptin and Metformin offers:
Dual glucose control and insulin sensitivity
Increased GI side effects
Delayed efficacy
Decreased renal safety
Jalra M’s bioavailability is better because of:
Controlled-release polymer coating
Optimized formulation purity and dissolution
Higher metformin content
Use of enteric coating
Jalra M contributes to:
Long-term β-cell health and durable glycemic control
Early insulin dependence
Increased triglyceride levels
Short-term glycemic spikes
The overall brand message of Jalra M can be summarized as:
Purer, better, and clinically consistent Vildagliptin + Metformin
Fastest acting gliptin combination
Cheapest DPP-4 inhibitor
Suitable for type 1 diabetes
